Effects of Crocin on Rotational Behavior, Lipid Peroxidation and Nitrite Levels in Rat’s Brain Striatum in an Experimental Model of Parkinson's Disease

Document Type : Original Article (s)

Authors

1 MSc Student, Department of Physiology, School of Medicine AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Professor, Neurosciences Research Center AND Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Degeneration of the nigrostriatal dopaminergic system is the pathologic hallmark of Parkinson's disease (PD), which leads to movement disorders. Compelling evidence implicates that oxidative stress plays an important role in degeneration of dopaminergic neurons in the disease. The aim of this study was to investigate the neuroprotective effect of crocin, a potent antioxidant in saffron, in an experimental model of Parkinson's disease in rat.Methods: 32 adult male Wistar rats were randomly divided into 4 groups of 8 including sham, parkinsonian and parkinsonian treated with crocin at doses of 30 and 60 mg/kg. 6-hydroxydopamine (6-OHDA) (16 µg in 0.2% ascorbate-saline) was infused into the left medial forebrain bundle. Crocin was injected intraperitoneally from 3 days before the surgery until 6 weeks. Rats were tested for rotational behavior by injection of apomorphine hydrochloride (2 mg/kg, intraperitoneally) at the weeks 2, 4 and 6. Malondialdehyde and nitrite levels were measured in the striatum at the end of the week 6.Findings: The apomorphine-induced contralateral body rotations were highly significant in parkinsonian group at the end of the weeks 2, 4 and 6 compared to the sham group (P < 0.001). Treatment of parkinsonian rats with crocin at the doses of 30 and 60 mg/kg did not change the rotations compared to the parkinsonian group. Malondialdehyde and nitrite levels in the striatum were significantly increased in parkinsonian group compared to the sham group (P < 0.050). Treatment of parkinsonian rats with crocin at a dose of 60 mg/kg significantly decreased the nitrite levels in the striatum compared to the parkinsonian rats (P < 0.05). However, treatment with crocin had no effect on malondialdehyde levels in the striatum.Conclusion: According to the present study, it seems that crocin at a dose of 60 mg/kg is effective on preventing the nitrosative stress in an experimental model of Parkinson's disease. However, crocin has no effect on improvement of rotational behavior and oxidative damage.

Keywords

References

  1. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39(6): 889-909.
  2. Olanow CW. The pathogenesis of cell death in Parkinson's disease--2007. Mov Disord 2007; 22(Suppl 17): S335-S342.
  3. Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 2006; 7(3): 207-19.
  4. Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007; 208(1): 1-25.
  5. Tsang AH, Chung KK. Oxidative and nitrosative stress in Parkinson's disease. Biochim Biophys Acta 2009; 1792(7): 643-50.
  6. Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson's disease. J Parkinsons Dis 2013; 3(4): 461-91.
  7. Semchuk KM, Love EJ, Lee RG. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 1993; 43(6): 1173-80.
  8. Schapira AH. Mitochondrial complex I deficiency in Parkinson's disease. Adv Neurol 1993; 60: 288-91.
  9. Lin TK, Cheng CH, Chen SD, Liou CW, Huang CR, Chuang YC. Mitochondrial dysfunction and oxidative stress promote apoptotic cell death in the striatum via cytochrome c/caspase-3 signaling cascade following chronic rotenone intoxication in rats. Int J Mol Sci 2012; 13(7): 8722-39.
  10. Deumens R, Blokland A, Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 2002; 175(2): 303-17.
  11. Truong L, Allbutt H, Kassiou M, Henderson JM. Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions. Behav Brain Res 2006; 169(1): 1-9.
  12. Prasad KN, Cole WC, Kumar B. Multiple antioxidants in the prevention and treatment of Parkinson's disease. J Am Coll Nutr 1999; 18(5): 413-23.
  13. Kostrzewa RM, Kostrzewa JP, Brus R. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Amino Acids 2002; 23(1-3): 57-63.
  14. Jomova K, Valko M. Health protective effects of carotenoids and their interactions with other biological antioxidants. Eur J Med Chem 2013; 70: 102-10.
  15. Rios JL, Recio MC, Giner RM, Manez S. An update review of saffron and its active constituents. Phytother Res 1996; 10(3): 189-93.
  16. He SY, Qian ZY, Tang FT, Wen N, Xu GL, Sheng L. Effect of crocin on experimental atherosclerosis in quails and its mechanisms. Life Sci 2005; 77(8): 907-21.
  17. Magesh V, Singh JP, Selvendiran K, Ekambaram G, Sakthisekaran D. Antitumour activity of crocetin in accordance to tumor incidence, antioxidant status, drug metabolizing enzymes and histopathological studies. Mol Cell Biochem 2006; 287(1-2): 127-35.
  18. Zheng YQ, Liu JX, Wang JN, Xu L. Effects of crocin on reperfusion-induced oxidative/nitrative injury to cerebral microvessels after global cerebral ischemia. Brain Res 2007; 1138: 86-94.
  19. Ochiai T, Shimeno H, Mishima K, Iwasaki K, Fujiwara M, Tanaka H, et al. Protective effects of carotenoids from saffron on neuronal injury in vitro and in vivo. Biochim Biophys Acta 2007; 1770(4): 578-84.
  20. Hosseinzadeh H, Sadeghnia HR, Ghaeni FA, Motamedshariaty VS, Mohajeri SA. Effects of saffron (Crocus sativus L.) and its active constituent, crocin, on recognition and spatial memory after chronic cerebral hypoperfusion in rats. Phytother Res 2012; 26(3): 381-6.
  21. Rajaei Z, Hadjzadeh MA, Nemati H, Hosseini M, Ahmadi M, Shafiee S. Antihyperglycemic and antioxidant activity of crocin in streptozotocin-induced diabetic rats. J Med Food 2013; 16(3): 206-10.
  22. Tamaddonfard E, Farshid AA, Eghdami K, Samadi F, Erfanparast A. Comparison of the effects of crocin, safranal and diclofenac on local inflammation and inflammatory pain responses induced by carrageenan in rats. Pharmacol Rep 2013; 65(5): 1272-80.
  23. Naghizadeh B, Mansouri MT, Ghorbanzadeh B, Farbood Y, Sarkaki A. Protective effects of oral crocin against intracerebroventricular streptozotocin-induced spatial memory deficit and oxidative stress in rats. Phytomedicine 2013; 20(6): 537-42.
  24. Hosseinzadeh H, Sadeghnia HR, Ziaee T, Danaee A. Protective effect of aqueous saffron extract (Crocus sativus L.) and crocin, its active constituent, on renal ischemia-reperfusion-induced oxidative damage in rats. J Pharm Pharm Sci 2005; 8(3): 387-93.
  25. Hosseinzadeh H, Modaghegh MH, Saffari Z. Crocus sativus L. (Saffron) extract and its active constituents (crocin and safranal) on ischemia-reperfusion in rat skeletal muscle. Evid Based Complement Alternat Med 2009; 6(3): 343-50.
  26. Chen Y, Zhang H, Tian X, Zhao C, Cai L, Liu Y, et al. Antioxidant potential of crocins and ethanol extracts of Gardenia jasminoides ELLIS and Crocus sativus L.: A relationship investigation between antioxidant activity and crocin contents. Food Chemistry 2008; 109(3): 484-92.
  27. Mousavi SH, Tayarani NZ, Parsaee H. Protective effect of saffron extract and crocin on reactive oxygen species-mediated high glucose-induced toxicity in PC12 cells. Cell Mol Neurobiol 2010; 30(2): 185-91.
  28. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 5th ed. London, UK: Academic Press; 2005.
  29. Fujita M, Nishino H, Kumazaki M, Shimada S, Tohyama M, Nishimura T. Expression of dopamine transporter mRNA and its binding site in fetal nigral cells transplanted into the striatum of 6-OHDA lesioned rat. Brain Res Mol Brain Res 1996; 39(1-2): 127-36.
  30. Sharma JB, Sharma A, Bahadur A, Vimala N, Satyam A, Mittal S. Oxidative stress markers and antioxidant levels in normal pregnancy and pre-eclampsia. Int J Gynaecol Obstet 2006; 94(1): 23-7.
  31. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 1968; 5(1): 107-10.
  32. Shapiro RM, Glick SD, Camarota NA. A two-population model of rat rotational behavior: effects of unilateral nigrostriatal 6-hydroxydopamine on striatal neurochemistry and amphetamine-induced rotation. Brain Res 1987; 426(2): 323-31.
  33. Schwarting RK, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 1996; 50(2-3): 275-331.
  34. Wypijewska A, Galazka-Friedman J, Bauminger ER, Wszolek ZK, Schweitzer KJ, Dickson DW, et al. Iron and reactive oxygen species activity in parkinsonian substantia nigra. Parkinsonism Relat Disord 2010; 16(5): 329-33.
  35. Dexter DT, Holley AE, Flitter WD, Slater TF, Wells FR, Daniel SE, et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 1994; 9(1): 92-7.
  36. Venkateshappa C, Harish G, Mythri RB, Mahadevan A, Bharath MM, Shankar SK. Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson's disease. Neurochem Res 2012; 37(2): 358-69.
  37. Esposito E, Rotilio D, Di M, V, Di GC, Cacchio M, Algeri S. A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes. Neurobiol Aging 2002; 23(5): 719-35.
  38. Glinka YY, Youdim MB. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol 1995; 292(3-4): 329-32.
  39. Roghani M, Niknam A, Jalali-Nadoushan MR, Kiasalari Z, Khalili M, Baluchnejadmojarad T. Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism. Brain Res Bull 2010; 82(5-6): 279-83.
  40. Mansouri MT, Farbood Y, Sameri MJ, Sarkaki A, Naghizadeh B, Rafeirad M. Neuroprotective effects of oral gallic acid against oxidative stress induced by 6-hydroxydopamine in rats. Food Chem 2013; 138(2-3): 1028-33.
  41. Khan MM, Ahmad A, Ishrat T, Khan MB, Hoda MN, Khuwaja G, et al. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res 2010; 1328: 139-51.
  42. Li M, Dai FR, Du XP, Yang QD, Chen Y. Neuroprotection by silencing iNOS expression in a 6-OHDA model of Parkinson's disease. J Mol Neurosci 2012; 48(1): 225-33.
  43. Reynolds MR, Berry RW, Binder LI. Nitration in neurodegeneration: deciphering the "Hows" "nYs". Biochemistry 2007; 46(25): 7325-36.
  44. Jalali-Nadoushan M, Roghani M. Alpha-lipoic acid protects against 6-hydroxydopamine-induced neurotoxicity in a rat model of hemi-parkinsonism. Brain Res 2013; 1505: 68-74.
  45. Guo S, Yan J, Yang T, Yang X, Bezard E, Zhao B. Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathway. Biol Psychiatry 2007; 62(12): 1353-62.
Journal of Isfahan Medical School
Volume 33, Issue 336 - Serial Number 336
March and April 2015
Pages 780-791

Files

History

  • Receive Date: 10 January 2015
  • Revise Date:
  • Accept Date: 06 April 2022

Share

How to cite

Statistics